Chiral diaryl macrocycles and uses thereof
AssigneeTurning Point Therapeutics, Inc.
InventorsJingrong J. Cui, Yishan Li, Evan W. Rogers, Dayong Zhai, Wei Deng, Zhongdong Huang
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans.
Claims20
A method of treating a cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of Compound 1:
- or a pharmaceutically acceptable salt thereof,
- wherein the cancer is mediated by a kinase selected from the group consisting of ALK, ROS1, TRKA, TRKB, TRKC, JAK1, JAK2, JAK3, SRC, FYN, LYN, YES, FGR, FAK, and ARK5.
A method of treating a cancer in a patient, comprising:
- (i) identifying a genetically altered kinase selected from the group consisting of ALK, ROS1, TRKA, TRKB, TRKC, JAK1, JAK2, JAK3, SRC, FYN, LYN, YES, FGR, FAK, and ARK5, in the patient, and
- (ii) administering to the patient a therapeutically effective amount of Compound 1:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.